The Bilski and Classen decisions can render numerous in vitro diagnostic claims unpatentable.
Michael R. Samardzija, PhD
Advertisement
Michael R. Samardzija, PhD, is counsel at Bracewell & Guiliani LLP
Articles by Michael R. Samardzija, PhD
Advertisement
Latest Updated Articles
Recent Patent Rulings Can Impede the Progress of Personalized MedicinePublished: August 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
4
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
5
